Cardinal Health Inc. reported fiscal 2026 third‑quarter revenue of $60.9 billion, up 11% year‑over‑year, and non‑GAAP diluted earnings per share of $3.17, a 35% increase over the same period in 2025. The company’s non‑GAAP operating earnings rose 18% to $956 million, while GAAP operating earnings fell 30% to $509 million, reflecting a $184 million goodwill impairment related to the Navista and ION reporting units.
The Pharmaceutical and Specialty Solutions segment drove the majority of the growth, generating $56.1 billion in revenue—an 11% increase—and $784 million in profit, up 18% from Q3 2025. In contrast, the Global Medical Products and Distribution segment saw flat revenue of $3.15 billion and a 36% decline in profit to $25 million, largely due to $200 million of IEEPA tariff payments. The Other segment grew 31% in revenue to $1.7 billion and added $179 million in profit, supported by at‑home solutions, nuclear and precision health, and logistics services.
Cardinal Health’s adjusted free cash flow for the quarter was $1.7 billion, indicating strong cash generation despite the goodwill charge. Management highlighted disciplined cost management and a favorable mix shift toward higher‑margin specialty products as key drivers of the earnings beat. The company also noted that the revenue miss relative to analyst consensus of $62.11–$62.35 billion was primarily due to weaker demand in legacy product lines and ongoing tariff headwinds.
Guidance for fiscal 2026 was raised, with non‑GAAP diluted EPS now projected at $10.70–$10.80, up from the prior $10.15–$10.35 range. The company reiterated its confidence in sustaining growth in the Pharmaceutical and Specialty Solutions segment and its managed services organization, while acknowledging continued tariff impacts in the Global Medical Products and Distribution business.
Investors reacted cautiously, focusing on the revenue miss despite the earnings beat and guidance upgrade. The market’s emphasis on top‑line performance underscores the importance of sustained revenue growth in a highly competitive wholesale environment, while the company’s ability to maintain profitability signals strong operational execution.
Overall, Cardinal Health’s Q3 results demonstrate resilience in its core specialty business, a challenging legacy segment, and a clear path forward through strategic investments and cost discipline. The raised guidance reflects management’s confidence in the company’s long‑term trajectory, even as tariff headwinds and goodwill impairment present short‑term challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.